Evidence map›Paper›PMID 24751386›Full record

ArticleThe Kaohsiung journal of medical sciences2014

Relationship between metalloproteinase 2 and 9 concentrations and soluble CD154 expression in Iranian patients with multiple sclerosis.

Javad Sanchooli, Nourollah Ramroodi, Nima Sanadgol, Vida Sarabandi, Hadi Ravan, Reza Saebi Rad

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Javad SanchooliDepartment of Immunology, Zabol University of Medical Sciences, Zabol, Iran.
Nourollah RamroodiDepartment of Neurology, Zahedan University of Medical Sciences, Zahedan, Iran.
Nima SanadgolDepartment of Biology, Faculty of Science, Zabol University, Zabol, Iran; Pharmaceutical Science Research Center (PSRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran. Electronic address: n.sanadgol@uoz.ac.ir.
Vida SarabandiDepartment of Biology, Faculty of Science, Zabol University, Zabol, Iran.
Hadi RavanDepartment of Biology, Faculty of Science, Shahid Bahonar University, Kerman, Iran.
Reza Saebi RadDepartment of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Zabol University · IRMashhad University of Medical Sciences · IRShahid Bahonar University of Kerman · IRZabol University of Medical Sciences · IRZahedan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrix metalloproteinases (MMPs) play a critical role in the blood-brain barrier permeability and in invasion of the leukocytes into the central nervous system during multiple sclerosis (MS). In this respect, in the present study, we have evaluated the possible role of MMP-9 and MMP-2 on the expression of soluble CD154 (sCD154) and membrane-bound isoform of the CD154 in Iranian MS patients. The expressions of the aforementioned protein-related genes were analyzed at the levels of messenger RNA and proteins by real-time reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blotting. The results showed a high expression of CD154 isoforms, MMP-9 and MMP-2, in MS patients in contrast to controls (p < 0.001). We found an increase in sCD154 concentration (i.e., >3-fold) in patients with a higher MMPs/tissue inhibitor of metalloproteinase 1 (TIMP-1) ratio. Furthermore, secondary-progressive MS patients with exacerbate period showed higher positive correlation between increasing sCD154 concentration and overexpression of MMP-2 (p < 0.001). Our data demonstrate that following the exacerbation period, sCD154 concentration is increased in patients, which is mutually related to the MMPs/TIMP-1 ratio. This relationship may represent a new link between sCD154 concentration and the MMPs/TIMP-1 ratio with prognostic implications.

Indexed as

AdolescentAdultBlotting, WesternCase-Control StudiesCD40 LigandFemaleHumansIranMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9Middle AgedMultiple SclerosisProtein IsoformsRNA, MessengerSolubilityCD40 LigandMatrix Metalloproteinase 2Matrix Metalloproteinase 9Protein IsoformsRNA, MessengerTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1Matrix metalloproteinase-2 and matrix metalloproteinase-9Multiple sclerosisSoluble CD40 ligandTissue inhibitors of metalloproteinase 1

Identifiers

PMID24751386
PMCPMC11915903
OpenAlexW2018171131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.